GRFS (Grifols) PE Ratio without NRI: 10.23 (As of Jun. 26, 2026) — 65% Below Median


GRFS Grifols SA GRFS
84 GF Score
Price $7.36
GF Value $8.79
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grifols PE Ratio without NRI?

Grifols GRFS +2.08% 84 PE Ratio without NRI is 10.23 as of Jun. 26, 2026, which is 65% below its 10-year median of 29.24. GuruFocus rates GRFS with a GF Score™ of 84/100 and a GF Value™ of $8.79 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 653 Drug Manufacturers companies, Grifols ranks better than 66% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-26), Grifols's share price is $7.355. Grifols's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.72. Therefore, Grifols's PE Ratio without NRI for today is 10.23.

During the past 13 years, Grifols's highest PE Ratio without NRI was 140.11. The lowest was 10.04. And the median was 29.24.

Grifols's EPS without NRI for the three months ended in Mar. 2026 was $0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.72.

As of today (2026-06-26), Grifols's share price is $7.355. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71. Therefore, Grifols's PE Ratio (TTM) for today is 10.39.

Good Sign:

Grifols SA stock PE Ratio (=14.79) is close to 10-year low of 14.69.

During the past years, Grifols's highest PE Ratio (TTM) was 140.11. The lowest was 10.20. And the median was 29.45.

Grifols's EPS (Diluted) for the three months ended in Mar. 2026 was $0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71.

Grifols's EPS (Basic) for the three months ended in Mar. 2026 was $0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71.


Grifols  (NAS:GRFS) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Grifols PE Ratio without NRI Related Terms


Grifols PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Grifols's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols PE Ratio without NRI Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.51 43.25 200.71 32.44 17.34

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.47 23.31 22.21 17.34 14.52

GRFS vs LLY, JNJ, ABBV: PE Ratio without NRI Comparison

For the Drug Manufacturers - General subindustry, Grifols's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Grifols's PE Ratio without NRI falls into.


GRFS
84GF Score
Grifols SA GRFS
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Grifols's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=7.355/0.719
=10.23

Grifols's Share Price of today is $7.355.
Grifols's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.72.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 10.23 mean?
Grifols (GRFS) has a PE Ratio without NRI of 10.23 as of Jun. 26, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Grifols and its competitors. This is 65% below median its historical median of 29.24. Over the past decade, Grifols' PE Ratio without NRI has ranged from 10.04 to 140.11. According to the industry distribution chart, Grifols ranks #222 out of 653 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Grifols' PE Ratio without NRI too high?
Grifols' current PE Ratio without NRI of 10.23 is 65% below median its 10-year median of 29.24. Over the past 10 years, this metric has ranged from a low of 10.04 to a high of 140.11. The Drug Manufacturers industry median PE Ratio without NRI is 20.30. Grifols' value of 10.23 is 49.6% below this industry median. Based on the distribution chart, Grifols ranks #222 out of 653 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' PE Ratio without NRI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #222 out of 653 companies for PE Ratio without NRI. This puts Grifols in the upper half of its industry. The industry median PE Ratio without NRI is 20.30. Grifols' value of 10.23 is 49.6% below this benchmark. Historically, Grifols' own PE Ratio without NRI has ranged from 10.04 to 140.11 over the past decade. While the company's 10-year median is 29.24 vs. the industry median of 20.30, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.30, based on 653 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current PE Ratio without NRI of 10.23 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current PE Ratio without NRI is 10.23, which is 65% below median its own 10-year median of 29.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.79, compared to a current price of $7.36 — trading 16.3% below its estimated fair value. The current PE Ratio without NRI is 10.23, which is 65% below median its 10-year median of 29.24 and 49.6% below the Drug Manufacturers industry median of 20.30. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Grifols (GRFS), the current PE Ratio without NRI is 10.23 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.36 is trading 16.3% below its estimated GF Value™ of $8.79. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • PE Ratio without NRI: 10.23 (65% below median its 10-year median of 29.24)
  • GF Value™: $8.79 vs. price of $7.36 (16.3% below fair value)
  • GF Score™: 84/100 with 6 warning signs
  • Industry Position: 49.6% below the Drug Manufacturers median (#222 of 653)

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score

Get the complete analysis for GRFS

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$8.79
GF Value